Overview

Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer

Status:
Terminated

Trial end date:
2018-05-22

Target enrollment:

Participant gender:

Summary

The purpose of this study was to evaluate the efficacy and safety of the combination of nivolumab plus epacadostat in combination with platinum chemotherapy compared with platinum chemotherapy alone, in participants with treatment-naïve Stage 4 or recurrent non-small cell lung cancer (NSCLC).

Phase:

Phase 3

Details

Lead Sponsor:

Incyte Corporation

Collaborator:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Carboplatin
Cisplatin
Gemcitabine
Nivolumab
Paclitaxel
Pemetrexed